Eisai Co-promotes "PyloriTek(R) Test Kit", H. Pylori Infection Diagnostic Kit Launched by Sanko Junyaku
November 28, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Eisai Co-promotes
Share:
Eisai Co-promotes "PyloriTek(R) Test Kit", H. Pylori Infection Diagnostic Kit Launched by Sanko Junyaku

Tokyo, July 27, 2007 - (JCN Newswire) - Sanko Junyaku Co., Ltd. today announced that it will launch the PyloriTek(R) Test Kit, a diagnostic kit for detecting Helicobacter pylori (H. pylori) infection in gastric biopsy specimens. The PyloriTek(R) Test Kit will be introduced to the market by Sanko Junyaku in September 2007 in co-promotion with its parent company Eisai Co., Ltd.

H. pylori is a type of bacterium in the human stomach and has been known to be deeply associated with peptic ulcers. The H. pylori eradication therapy has shown efficacy in reducing the risk for ulcer recurrence, providing a great benefit for patients.

The PyloriTek(R) Test Kit is a diagnostic product used in the presumptive identification of H. pylori infection before and after the eradication therapy to evaluate infectious status of the patients. The PyloriTek(R) Test Kit shortens the diagnostic testing procedures due to the simplified preparation, enabling the test to start at the earliest opportunity. In addition, easier result evaluation can be made possible by the large reaction pad on which a positive reaction appears as an intense color change.

Eisai Group established the Japan Business Headquarters in April 2007 which facilitates provision of information, services and products under the business strategy unified by all four domestic operations of Eisai Group (diagnostics/prescription pharmaceuticals/consumer healthcare products/generics). Eisai Co., Ltd. which co-promotes the PyloriTek(R) Test Kit has been marketing Pariet(R) (generic name: rabeprazole sodium), the company's core proton pump inhibitor which is approved for H. pylori eradication therapy in combination with antibiotics.

From diagnostics to treatment, Sanko Junyaku and Eisai provide a wide range of products and information for H. pylori infection, thereby making further contributions to the treatment of acid related disorders and improve the QOL (Quality of Life) of patients with peptic ulcers.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:

Kazunori Nishina
Investor Relations,
Sanko Junyaku Co., Ltd.
TEL: +81-3-3865-4311

Corporate Communications Department,
Eisai Co., Ltd.
TEL: +81-3-3817-5120
 


July 27, 2007
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)